Prescription medicine
Ramucirumab Brand names: Cyramza
Ramucirumab (Cyramza) is a prescription medicine with an FDA approval on record since 2014. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the ramucirumab FDA label on DailyMed (effective June 9, 2026, Eli Lilly and Company); the BLA 125477 record on Drugs@FDA; every ramucirumab label on DailyMed.
Highlights of the record
FDA label of June 9, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageCYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
Forms and strengths
- 10 mg/ml
Solution.
On the market
- Earliest approval on file
- April 21, 2014 Cyramza, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2019 0 Class I among all firms' recalls; latest June 12, 2019
- FAERS reports
- 6,218 through July 30, 2026
What is ramucirumab used for?
From the label: indications and usageCYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. […]
Conditions named in the indications of ramucirumab's FDA labels, with every medicine labeled for each:
From other ramucirumab labelsLung cancer: … with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. …
Colorectal cancer: … ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. …
FDA pharmacologic class: Vascular Endothelial Growth Factor Receptor 2 Antagonist.
Source: FDA drug label (CYRAMZA), Eli Lilly and Company, effective June 9, 2026 (SPL set c6080942-dee6-423e-b688-1272c2ae90d4), via openFDA; the full label on DailyMed
Is there a generic for ramucirumab (Cyramza)?
No generic ramucirumab is approved (Drugs@FDA, October 8, 2026).
- 2014 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has ramucirumab been recalled?
The FDA's Enforcement Report lists 1 recall naming ramucirumab since 2019: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 12, 2019 | Class II | Infusion Options, Inc. | Lack of Assurance of Sterility |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ramucirumab label say about other medicines?
The ramucirumab label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | warnings and precautions | In addition, patients with NSCLC with a recent history of gross hemoptysis, those receiving chronic therapy with NSAIDs or other anti-platelet therapy other than once daily aspirin, or with radiographic evidence of major blood vessel invasion or intratumor cavitation were excluded from REVEL and RELAY; … |
| Erlotinib | warnings and precautions | In 221 patients with NSCLC receiving CYRAMZA in combination with erlotinib in the RELAY study, the incidence of new or worsening hypertension was higher (45%), as was the incidence of Grade 3-5 hypertension (24%). |
Source: FDA drug label (CYRAMZA), Eli Lilly and Company, effective June 9, 2026 (SPL set c6080942-dee6-423e-b688-1272c2ae90d4), via openFDA; the full label on DailyMed
What do FAERS reports show for ramucirumab?
The FDA Adverse Event Reporting System holds 6,218 reports that list ramucirumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,653 are coded as a death and 2,369 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ramucirumab?
18 other medicines are given the same way (intravenous) and in the same FDA class as ramucirumab or labeled mainly for the same use (lung cancer), the same class first. Lung cancer lists all 55 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Pemetrexed | Lung cancer | 15 labelers | n/a | A presentation being discontinued |
| Etoposide | Lung cancer | 5 labelers | n/a | No current entry |
| Bevacizumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Topotecan | Lung cancer | 4 labelers | n/a | No current entry |
| Nivolumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Bevacizumab-maly | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Ipilimumab | Lung cancer, Colorectal cancer | none listed | n/a | No current entry |
| Atezolizumab | Lung cancer | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as ramucirumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to ramucirumab
- 18 medicines for the same use
- Ramucirumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other